26 Jan 2022 18:27
Sensyne Health plc
("Sensyne" or the "Company")
Publication of Circular and Notice of General Meeting
Oxford, U.K. -26 January 2022: Sensyne Health plc (LSE:SENS), the UK clinical AI company, announces that further to the announcement at 7.00 a.m. today of the successful completion of the Financing, a Circular has been published on the Company's website, www.sensynehealth.com, and will be posted to Shareholders today. The Circular contains the notice convening the General Meeting to be held at 2.00 p.m. on 11 February 2022.
The Board takes the health, safety, and wellbeing of all of the Company's stakeholders very seriously and Shareholders should note that as a result of the COVID-19 pandemic and the guidance published by the UK Government, physical attendance at the General Meeting may not be possible at the time of the meeting. In addition, and in accordance with the Articles, the Company may impose entry restrictions on attendance at the General Meeting. In light of this, the Board encourages Shareholders to submit their votes by proxy in advance by the required deadline of 2.00 p.m. on 9 February 2022 and to appoint the Chairman of the meeting as their proxy, with voting instructions, to ensure their vote is counted. If the Company intends to restrict physical attendance at the General Meeting, the Company will notify Shareholders of this, or any other change to the proposed format of the General Meeting, as soon as possible via RNS and its website at www.sensynehealth.com.
Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the definitions section included in Appendix I of the announcement made at 7.00 a.m. today via RNS.
-ENDS-
Contact details:
Sensyne Health |
| ||
Dr Richard Pye, Chief Financial Officer
| +44 (0) 330 058 1845 |
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
| |
Dr Christopher Golden James Steel
|
| ||
Liberum (Joint Broker) | |||
Bidhi Bhoma Phil Walker William Hall | + 44 (0) 20 3100 2000 | ||
Consilium Strategic Communications | |||
Mary-Jane Elliott Jessica Hodgson CSCSensynehealth@consilium-comms.com | +44 (0) 7780 600290 | ||
SternIR | |||
Julie Seidel Julie.seidel@sternir.com | +1 (212) 362 1200 | ||
Notes for editors:
About Sensyne Health: https://www.sensynehealth.com/
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
SENS.L (SENS)